ODI Pharma AB (publ) (NGM:ODI)

ODI Pharma AB Statistics

Total Valuation

ODI Pharma AB has a market cap or net worth of SEK 75.52 million. The enterprise value is 70.76 million.

Market Cap	75.52M
Enterprise Value	70.76M

Important Dates

The last earnings date was Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

ODI Pharma AB has 18.33 million shares outstanding. The number of shares has increased by 29.48% in one year.

Current Share Class	18.33M
Shares Outstanding	18.33M
Shares Change (YoY)	+29.48%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	90.68%
Owned by Institutions (%)	n/a
Float	1.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.77
PB Ratio	39.04
P/TBV Ratio	39.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-97.65
EV / Sales	3.53
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.24

Current Ratio	1.24
Quick Ratio	1.23
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-0.43

Financial Efficiency

Return on equity (ROE) is -60.91% and return on invested capital (ROIC) is -14.66%.

Return on Equity (ROE)	-60.91%
Return on Assets (ROA)	-2.11%
Return on Invested Capital (ROIC)	-14.66%
Return on Capital Employed (ROCE)	-14.42%
Weighted Average Cost of Capital (WACC)	8.33%
Revenue Per Employee	20.04M
Profits Per Employee	-724,671
Employee Count	1
Asset Turnover	2.42
Inventory Turnover	n/a

Taxes

In the past 12 months, ODI Pharma AB has paid 4,228 in taxes.

Income Tax	4,228
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +82.46% in the last 52 weeks. The beta is 0.74, so ODI Pharma AB's price volatility has been lower than the market average.

Beta (5Y)	0.74
52-Week Price Change	+82.46%
50-Day Moving Average	3.74
200-Day Moving Average	2.31
Relative Strength Index (RSI)	56.42
Average Volume (20 Days)	15,985

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ODI Pharma AB had revenue of SEK 20.04 million and -724,671 in losses. Loss per share was -0.04.

Revenue	20.04M
Gross Profit	5.97M
Operating Income	-279,066
Pretax Income	-720,443
Net Income	-724,671
EBITDA	-276,312
EBIT	-279,066
Loss Per Share	-0.04

Balance Sheet

The company has 4.76 million in cash and n/a in debt, with a net cash position of 4.76 million or 0.26 per share.

Cash & Cash Equivalents	4.76M
Total Debt	n/a
Net Cash	4.76M
Net Cash Per Share	0.26
Equity (Book Value)	1.93M
Book Value Per Share	0.11
Working Capital	1.92M

Cash Flow

Operating Cash Flow	-685,117
Capital Expenditures	n/a
Depreciation & Amortization	2,754
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 29.79%, with operating and profit margins of -1.39% and -3.62%.

Gross Margin	29.79%
Operating Margin	-1.39%
Pretax Margin	-3.60%
Profit Margin	-3.62%
EBITDA Margin	-1.38%
EBIT Margin	-1.39%
FCF Margin	n/a

Dividends & Yields

ODI Pharma AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.48%
Shareholder Yield	-29.48%
Earnings Yield	-0.96%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3